Lupin Limited · NSE:LUPIN
Lupin — Q1 FY2020 Earnings Presentation
15 slides from Lupin's earnings presentation, Aug 8, 2019
Slide 1: Covering letter to BSE and NSE
LUPIN August 8, 2019 BSE Limited Department of Corporate Services, P. J. Towers, Dalai Street, MUMBA1 - 400 001. .7ational Stock Exchange of India limited Exchange Plaza, Bandra Kuria Complex, Bandra (East), Mumbai - 400 051. Dear Sirs, Sub: Q1 FY2020 Investor Presentation. Pursuant to Regulation 30
Slide 2: Investor presentation Q1 FY2020
LUPIN LIMITED Investor presentation Q1 FY2020 Aug 08, 2019
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • McKesson Supplier of the Year Award - 2019 • Walmart Supplier of the Year Award - 2018 • Cardinal Supply Chain Excellence Award – 2018 • Dr. Desh Bandhu Gupta inducted into the ‘Hall of Fame’, CNBC-TV18 – India Business Leader Awards 2018 • Vinita Gupta: Vogue and IBM
Slide 5: Q1 FY2020 Snapshot
Q1 FY2020 Snapshot Sales (INR mn, YoY growth) Important developments Commercial India, North America, • 5 new launches in the US including an inhalation 13,077 , 10% Mr. Nilesh.D.Gupta 15,412 , 30% Managing Director Lupin Limited and a dermatology generic Total • Continued to benefit from gRanexa ex
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Business Strong Complex Specialty Foundation Generics Focus Focus Amongst the Top 10 Focus on delivering high Committed to building a generic companies in the barrier products strong specialty business World Sustain and Grow Portfolio Execution Build • Major
Slide 7: Q1 FY2020 Financial Results Review
Q1 FY2020 Financial Results Review
Slide 8: P&L Highlights – Q1 FY2020
P&L Highlights – Q1 FY2020 QoQ YoY Amount in INR mn Q1 FY20 % of sales Q4 FY19 % of sales Q1 FY19 % of sales growth growth Net sales 43,558 100.0% 43,259 100.0% 0.7% 37,746 100.0% 15.4% Other operating income 626 804 814 Total revenue 44,184 44,063 0.3% 38,560 14.6% Gross profit 28,058 64.4% 29,181
Slide 9: North America
Q1FY20 North America 35% YoY QoQ 30.0% 11.5% US revenues buoyant driven by gRanexa and new launches Lupin consolidating its position in US1 US quarterly sales ($ mn) 245 218 31.4% average 194 market share1 168 171 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 US portfolio progressing • Complex generics -
Slide 10: India
Q1FY20 India 30% YoY QoQ 9.7% 24.2% India business continues to be robust Consistently outpacing industry growth India quarterly Sales (INR bn) 4 Year CAGR% Lupin Rank1 13.1 MAT MAT 11.9 12.0 11.9 Therapy Market Lupin 10.5 Jun-15 Jun-19 Acute 8% 7% 14 13 Chronic 11% 16% 5 4 Cardiac 9% 10% 2 3 Anti-d
Slide 11: APAC
Q1FY20 APAC 15% YoY QoQ 10.5% 2.7% APAC sales evolution (INR bn) Performance highlights 1.2 1.4 1.1 Japan 1.1 1.1 • Growth driven by strong volume uptick in 5.7 5.6 baseline products 5.0 5.1 5.5 • Maintained leadership (#1) in the generic CNS market (19% volume share) Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19
Slide 12: Developed and emerging markets
Other markets • Germany: EUR 7.8 mn sales in Q1 FY20 Developed • ARV’s, Women´s Health and CNS are the key focus therapeutic segments EU5 • NaMusclaTM - Launched with Orphan drug designation in UK, Germany and France; Partnering discussions in advanced stages for other EU markets • 5th largest gener
Slide 13: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence OPERATIONS 100 25 9 Countries where Countries with Countries with RESEARCH products are sold marketing offices subsidiaries 18 9 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 422 US ANDAs; 270 approved ◼ 30 bn+ ex
Slide 14: R&D – Higher focus on complex products and FTFs
R&D – Higher focus on complex products and FTFs Invested INR 3.8 bn or 8.7% of sales on R&D in Q1FY20 at 9 R&D sites globally Optimizing R&D spend US Pipeline 5.4 9.9% 9.7% 9.7% 4.8 9.2% 8.7% 10.0% 422 cumulative filings 4.2 8.0% 3.6 3.0 6.0% 2.4 4.3 4.0 3.8 4.0% 152 pending approval 1.8 3.8 3.8 1.2
Slide 15: Thank You!
ie YEARS OF LUPIN LUPIN THANK YOU!